Alnylam’s pipeline is built on small interfering RNA (siRNA), synthetic molecules that silence specific mRNAs. After nearly 15 years of investment in the field, Alnylam is now nearing the moment ...

RNA interference (RNAi) therapeutics silence genes, disrupting the production of proteins that contribute to disease. Scientists at Alnylam Pharmaceuticals have developed and are testing multiple RNAi ...

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Silence Therapeutics (SLN – Research Report) and keeping the price ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Alnylam Pharmaceuticals (ALNY) reports results for the quarter ended December 2024. While this widely-known ...

Has Alnylam Pharmaceuticals (ALNY) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us ...

Alnylam’s (ALNY) treatment of transthyretin-mediated amyloidosis, or ATTR amyloidosis, was granted FDA orphan designation, according to a post to the agency’s website. Published first on ...

Alnylam Pharmaceuticals (ALNY), a commercial-stage company, focuses on developing novel therapeutics based on RNAi. The ...

Is Alnylam Pharmaceuticals (ALNY) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out. Alnylam Pharmaceuticals is one of 1010 individual ...

Alnylam Pharmaceuticals stock advanced after the company said its preliminary 2024 product revenue rose 34%. The shares rose 8% to $256.87 Monday. They are up 37% over the past 12 months. The ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2024 global ...

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company ...